Diabetic Retinopathy: Early Diagnosis and Effective Treatment

Overview

Journal Dtsch Arztebl Int

Specialties General Medicine
Public Health

Date 2010 Feb 27

PMID 20186318

Citations 130

Authors

Aris N Kollias

Michael W Ulbig

Affiliations

Soon will be listed here.

Abstract

Background: Diabetic retinopathy is a microangiopathy of the retina from which nearly all persons with diabetes eventually suffer. Two of its complications threaten the patient's vision: diabetic macular edema and proliferative diabetic retinopathy.

Methods: Selective literature review, based on national and international guidelines and a literature search from 1981 onward.

Results: Diabetic retinopathy is subdivided into non-proliferative and proliferative retinopathy. Macular edema can arise at any stage of the disease and threatens visual acuity. The main risk factors for the development and progression of diabetic retinopathy are long duration of diabetes and poor control of blood sugar and arterial blood pressure. Laser photocoagulation is an evidence-based treatment for proliferative retinopathy and macular edema. Vitreous surgery is indicated in cases of worsening vision due to a non-clearing vitreous hemorrhage or tractional retinal detachment. The current options for medical treatment involve the intravitreous injection of glucocorticosteroids or of a VEGF antagonist; both of these options are "off label" at present.

Conclusion: Diabetic retinopathy is the leading cause of blindness among persons of working age in the industrialized world. Regular ophthalmological examinations, timely laser therapy depending on the stage of the disease, and close interdisciplinary cooperation are essential to prevent loss of vision.

Citing Articles

Type 2 Diabetes Mellitus: New Pathogenetic Mechanisms, Treatment and the Most Important Complications.

Mlynarska E, Czarnik W, Dzieza N, Jedraszak W, Majchrowicz G, Prusinowski F Int J Mol Sci. 2025; 26(3).

PMID: 39940862 PMC: 11817707. DOI: 10.3390/ijms26031094.

Tear glucose is associated with the presence and severity of diabetic retinopathy.

Cao N, Feng L, Xu W, He F, Xiao C, Liu Y Int J Retina Vitreous. 2025; 11(1):13.

PMID: 39915852 PMC: 11800454. DOI: 10.1186/s40942-025-00636-x.

Eye Axial Length: Is There a Protective Link to Diabetic Retinopathy?.

Mouzaka A, Chandrinos A, Chatziralli I, Chatzichristou E, Gialelis T Cureus. 2025; 16(12):e75712.

PMID: 39811241 PMC: 11731203. DOI: 10.7759/cureus.75712.

Detection of Disease Features on Retinal OCT Scans Using RETFound.

Du K, Nair A, Shah S, Gadari A, Vupparaboina S, Bollepalli S Bioengineering (Basel). 2025; 11(12.

PMID: 39768004 PMC: 11672910. DOI: 10.3390/bioengineering11121186.

Insight into dysregulated VEGF-related genes in diabetic retinopathy through bioinformatic analyses.

Wang X, He X, Li Z, Mu T, Pang L, Ma W Naunyn Schmiedebergs Arch Pharmacol. 2024; .

PMID: 39725717 DOI: 10.1007/s00210-024-03638-y.

References

Nathan D, Genuth S, Lachin J, Cleary P, Crofford O, Davis M . The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993; 329(14):977-86. DOI: 10.1056/NEJM199309303291401. View

Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving H . Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet. 2008; 372(9647):1394-402. DOI: 10.1016/S0140-6736(08)61412-9. View

Beck R, Edwards A, Aiello L, Bressler N, Ferris F, Glassman A . Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol. 2009; 127(3):245-51. PMC: 2754047. DOI: 10.1001/archophthalmol.2008.610. View

Sjolie A, Klein R, Porta M, Orchard T, Fuller J, Parving H . Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet. 2008; 372(9647):1385-93. DOI: 10.1016/S0140-6736(08)61411-7. View

Schmieder R, Martin S, Lang G, Bramlage P, Bohm M . Angiotensin blockade to reduce microvascular damage in diabetes mellitus. Dtsch Arztebl Int. 2009; 106(34-35):556-62. PMC: 2754668. DOI: 10.3238/arztebl.2009.0556. View

. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998; 352(9131):837-53. View

. Effect of ruboxistaurin in patients with diabetic macular edema: thirty-month results of the randomized PKC-DMES clinical trial. Arch Ophthalmol. 2007; 125(3):318-24. DOI: 10.1001/archopht.125.3.318. View

Rosenstock J, Fonseca V, McGill J, Riddle M, Halle J, Hramiak I . Similar progression of diabetic retinopathy with insulin glargine and neutral protamine Hagedorn (NPH) insulin in patients with type 2 diabetes: a long-term, randomised, open-label study. Diabetologia. 2009; 52(9):1778-88. PMC: 2723680. DOI: 10.1007/s00125-009-1415-7. View

Horle S, Gruner F, Kroll P . [Epidemiology of diabetes-induced blindness -- a review]. Klin Monbl Augenheilkd. 2002; 219(11):777-84. DOI: 10.1055/s-2002-36318. View

10.

Jonas J . Intravitreal triamcinolone acetonide for diabetic retinopathy. Dev Ophthalmol. 2007; 39:96-110. DOI: 10.1159/000098502. View

11.

Blum M, Kloos C, Muller N, Mandecka A, Berner R, Bertram B . [Prevalence of diabetic retinopathy. Check-up program of a public health insurance company in Germany 2002-2004]. Ophthalmologe. 2007; 104(6):499-500, 502-4. DOI: 10.1007/s00347-007-1522-0. View

12.

. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98(5 Suppl):766-85. View

13.

. Early vitrectomy for severe proliferative diabetic retinopathy in eyes with useful vision. Clinical application of results of a randomized trial--Diabetic Retinopathy Vitrectomy Study Report 4. The Diabetic Retinopathy Vitrectomy Study Research Group. Ophthalmology. 1988; 95(10):1321-34. DOI: 10.1016/s0161-6420(88)33014-9. View

14.

Cunningham Jr E, Adamis A, Altaweel M, Aiello L, Bressler N, DAmico D . A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology. 2005; 112(10):1747-57. DOI: 10.1016/j.ophtha.2005.06.007. View

15.

Gandorfer A, Kampik A . [Pars plana vitrectomy in diabetic retinopathy. From pathogenetic principle to surgical strategy]. Ophthalmologe. 2000; 97(5):325-30. DOI: 10.1007/s003470050531. View

16.

. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ. 1998; 317(7160):713-20. PMC: 28660. View

17.

Ulbig M, Kampik A, Hamilton A . [Diabetic retinopathy. Epidemiology, risk factors and staging]. Ophthalmologe. 1993; 90(2):197-209. View

18.

Campochiaro P . Reduction of diabetic macular edema by oral administration of the kinase inhibitor PKC412. Invest Ophthalmol Vis Sci. 2004; 45(3):922-31. DOI: 10.1167/iovs.03-0955. View

19.

Lanzagorta-Aresti A, Palacios-Pozo E, Menezo Rozalen J, Navea-Tejerina A . Prevention of vision loss after cataract surgery in diabetic macular edema with intravitreal bevacizumab: a pilot study. Retina. 2009; 29(4):530-5. DOI: 10.1097/IAE.0b013e31819c6302. View

20.

Chaturvedi N, Sjolie A, Stephenson J, Abrahamian H, Keipes M, Castellarin A . Effect of lisinopril on progression of retinopathy in normotensive people with type 1 diabetes. The EUCLID Study Group. EURODIAB Controlled Trial of Lisinopril in Insulin-Dependent Diabetes Mellitus. Lancet. 1998; 351(9095):28-31. DOI: 10.1016/s0140-6736(97)06209-0. View